In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
A quote shared during our bi-weekly Tuesday multiple myeloma support group, where five or more gather in the virtual Zoom ...
A study carried out by a team of researchers from The Institute of Cancer Research, London, found that combining two types of ...
The teclistamab-cqyv and daratumumab regimen achieved a 100% overall response rate and MRD negativity in newly diagnosed ...
A combination of genetic tests for a "very complex" blood cancer could accurately predict if the disease is likely to return ...
Scientists have identified a more accurate way of predicting which patients with multiple myeloma are likely to relapse early ...
International Myeloma Foundation (IMF) to hold AMN Awards Ceremony at the 9th AMN Summit in Nagoya, Japan on Saturday, ...
It is hoped it will allow medics to better understand how cancer cells are behaving before planning treatment.
Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson ...
“Our findings show that RNA-based testing can uncover hidden risks in multiple myeloma that DNA tests alone miss,” study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback